Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia.
D'Angelo
Armando
A
Servizio di Coagulazione ed Unita' Ricerca Trombosi, IRCCS H S. Raffaele, Milan, Italy. armando.dangelo@hsr.it
Valle
Patrizia Della
PD
Fattorini
Annalisa
A
Luciano
Crippa
C
D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use*; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010978:Platelet Factor 4 / Q000276:immunology; D011134:Polysaccharides / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D020246:Venous Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
D000906:Antibodies; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D010978:Platelet Factor 4; D000077425:Fondaparinux